The TekiTrust™ COVID-19 IgG Rapid Test is a lateral flow immunoassay intended for qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, venous whole blood (sodium heparin, lithium heparin, sodium citrate and tripotassium EDTA), plasma (sodium heparin, lithium heparin, sodium citrate and tripotassium EDTA), and fingerstick whole blood. The TekiTrust™ COVID-19 IgG Rapid Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The TekiTrust™ COVID-19 IgG Rapid Test should not be used to diagnose or exclude acute SARS-CoV-2 infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARSCoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion. The TekiTrust™ COVID-19 IgG Rapid Test is only for use under the Food and Drug Administration’s Emergency Use Authorization.